A lung cancer study found nearly 80% of patients alive at one year on two drugs, versus 53% on one.
Amgen's Phase 3 DeLLphi-305 study showed that 80% of patients with extensive-stage small cell lung cancer (ES-SCLC) treated with IMDELLTRA (tarlatamab) and durvalumab survived at one year, compared to 53% with durvalumab alone. The combination therapy also reduced the risk of disease progression or death by 66%. Amgen will discuss these results and its oncology portfolio in an upcoming investor event.
How this was made
The 30-second read
Why it matters
The data represent a significant efficacy improvement in extensive‑stage small cell lung cancer, a historically unmet need.
Market read
First‑report of pivotal trial data likely triggers immediate price moves in Amgen and AstraZeneca, with spillover to oncology biotech peers.
What to watch
Manufacturing scale‑up risk and pricing negotiations with payers could temper upside.
Background
The DeLLphi-305 trial data were presented at the ESMO Presidential Symposium and published in NEJM, marking the first public disclosure of these results.
Ticker impact
Amgen announced positive Phase 3 DeLLphi-305 results showing 80% 1‑year survival with IMDELLTRA+durvalumab versus 53% with durvalumab alone.
likely upward pressure as investors price in a new oncology asset.
First‑report of pivotal data for a first‑in‑class therapy; market typically reacts strongly to such breakthroughs.
AstraZeneca supplied durvalumab for the DeLLphi-305 trial and is a co‑partner in the positive results.
potential modest upside driven by association with successful trial.
While not the primary asset, AZN benefits from co‑development and may see incremental demand for durvalumab.
Market effects
Strengthens the broader oncology biotech sector and may boost peer valuations.
Positive for US biotech indices and European pharma markets where AstraZeneca trades.
Adds to global interest in DLL3‑targeted therapies, potentially influencing worldwide biotech sentiment.
Counterpoint
If regulatory scrutiny intensifies or safety concerns emerge, the rally could be short‑lived.
Key entities
- CompanyAmgen
Sponsor and developer of IMDELLTRA (tarlatamab).
- CompanyAstraZeneca
Provider of durvalumab, co‑partner in the trial.
- DrugIMDELLTRA (tarlatamab)
First‑in‑class DLL3‑targeted bispecific antibody.
